Patents by Inventor Eric Cleveland Bigham

Eric Cleveland Bigham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazoline derivatives as alpha-1A adrenoceptor ligands
    Patent number: 6884801
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 26, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Eric Cleveland Bigham, Michael Joseph Bishop, David Harold Drewry, Deanna Trojan Garrison, Stephen Joseph Hodson, Frank Navas, III, Jason D. Speake
  • Substituted urea and isothiourea derivatives as no synthase inhibitors
    Publication number: 20010034342
    Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.
    Type: Application
    Filed: January 26, 2001
    Publication date: October 25, 2001
    Inventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Cleveland Bigham, Eric Steven Furfine, Edward Patrick Garvey
  • Substituted urea and isothiourea derivatives as no synthase inhibitors
    Patent number: 6297276
    Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerbral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: October 2, 2001
    Assignee: GlaxoSmithKline
    Inventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Cleveland Bigham, Eric Steven Furfine, Edward Patrick Garvey
  • Substituted urea and isothiorea derivatives as no synthase inhibitors
    Patent number: 6225305
    Abstract: The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: May 1, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Jeffrey Alan Oplinger, Barry George Shearer, Eric Cleveland Bigham, Eric Steven Furfine, Edward Patrick Garvey
  • Substituted isoquinolines as ultra short acting neuromuscular blockers
    Patent number: 6187789
    Abstract: Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z1 and Z2 are methyl; W1 and W2 are carbon; and A is a pharmaceutically acceptable anion.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: February 13, 2001
    Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.
    Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano
  • Substituted isoquinolines as ultra short acting neuromuscular blockers
    Patent number: 6177445
    Abstract: Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X1 and X2 are independently halogen; ha and hb are independenity from 0 to 2; Z1 and Z2 are indepentdently hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl with the proviso that Z1 and Z2 are not both hydrogen; Y1, Y2, and Y3 and Y4 are independently hydrogen, halogen or C1-3 alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if ha and hb are both 0, then r is 0 and n is 0 to 2; R1 to R14 are independently hydrogen, halogen, C1-3 alkoxy, or R2 and R3 together with the carbon atoms to which they are bonded, R5 and R6 together with the carbon atoms to which they are bonded, R9 and R10 together with the carbon atoms to which they are bonded, R12 and R13 together with the carbon atoms to which they are bonded, may
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: January 23, 2001
    Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.
    Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano